Skye Bioscience (FRA:09R) Cyclically Adjusted Book per Share: €-8.86 (As of Mar. 2026)


FRA:09R Skye Bioscience Inc FRA:09R
12 GF Score
Price €0.56
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Cyclically Adjusted Book per Share?

Skye Bioscience FRA:09R 12 Cyclically Adjusted Book per Share is €-8.86 as of Mar. 2026. GuruFocus rates FRA:09R with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Skye Bioscience's adjusted book value per share for the three months ended in Mar. 2026 was €0.222. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-8.86 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Skye Bioscience was 1.40% per year. The lowest was 1.40% per year. And the median was 1.40% per year.

As of today (2026-07-04), Skye Bioscience's current stock price is €0.555. Skye Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €-8.86. Skye Bioscience's Cyclically Adjusted PB Ratio of today is .


Skye Bioscience  (FRA:09R) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Skye Bioscience Cyclically Adjusted Book per Share Related Terms


Skye Bioscience Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Cyclically Adjusted Book per Share Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -10.15

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.97 -10.48 -10.18 -10.15 -8.86

FRA:09R vs PLRZ, NEUP, LGVN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Skye Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skye Bioscience Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Cyclically Adjusted PB Ratio falls into.


FRA:09R
12GF Score
Skye Bioscience Inc FRA:09R
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Skye Bioscience's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.222/330.2130*330.2130
=0.222

Current CPI (Mar. 2026) = 330.2130.

Skye Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201606 -17.963 241.018 -24.611
201609 -26.500 241.428 -36.245
201612 -32.128 241.432 -43.942
201703 -24.697 243.801 -33.451
201706 -21.529 244.955 -29.022
201709 -22.024 246.819 -29.465
201712 -22.507 246.524 -30.148
201803 -8.804 249.554 -11.650
201806 -13.292 251.989 -17.418
201809 -16.298 252.439 -21.319
201812 -25.521 251.233 -33.544
201903 -46.007 254.202 -59.764
201906 -19.220 256.143 -24.778
201909 -27.785 256.759 -35.734
201912 0.673 256.974 0.865
202003 -2.102 258.115 -2.689
202006 -3.748 257.797 -4.801
202009 1.573 260.280 1.996
202012 0.322 260.474 0.408
202103 1.415 264.877 1.764
202106 1.190 271.696 1.446
202109 3.690 274.310 4.442
202112 2.726 278.802 3.229
202203 1.360 287.504 1.562
202206 -0.144 296.311 -0.160
202209 -1.672 296.808 -1.860
202212 -0.777 296.797 -0.864
202303 -1.149 301.836 -1.257
202306 -1.850 305.109 -2.002
202309 0.129 307.789 0.138
202312 -0.158 306.746 -0.170
202403 2.586 312.332 2.734
202406 2.410 314.175 2.533
202409 2.251 315.301 2.357
202412 2.101 315.605 2.198
202503 1.769 319.799 1.827
202506 1.222 322.561 1.251
202509 0.903 324.800 0.918
202512 0.512 324.054 0.522
202603 0.222 330.213 0.222

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-8.86 mean?
Skye Bioscience (FRA:09R) has a Cyclically Adjusted Book per Share of €-8.86 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Skye Bioscience and its competitors.
Is Skye Bioscience's Cyclically Adjusted Book per Share too high?
Skye Bioscience's current Cyclically Adjusted Book per Share is €-8.86. Overall, Skye Bioscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Cyclically Adjusted Book per Share compare to PLRZ and NEUP?
Skye Bioscience's Cyclically Adjusted Book per Share of €-8.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Skye Bioscience and its competitors. Skye Bioscience's current Cyclically Adjusted Book per Share is €-8.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Cyclically Adjusted Book per Share of €-8.86. The current Cyclically Adjusted Book per Share is €-8.86. Skye Bioscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Cyclically Adjusted Book per Share is €-8.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
12GF Score

Get the complete analysis for FRA:09R

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.56
Price